Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Massive haemoptysis after radiotherapy in inoperable non-small cell lung carcinoma: is endobronchial brachytherapy really a risk factor?
Autore:
Langendijk, JA; Tjwa, MKT; de Jong, JMA; ten Velde, GPM; Wouters, EFM;
Indirizzi:
Radiotherapeut Inst Limburg, Heerlen, Netherlands Radiotherapeut Inst Limburg Heerlen Netherlands g, Heerlen, Netherlands De Wever Hosp, Dept Resp Dis, Heerlen, Netherlands De Wever Hosp HeerlenNetherlands , Dept Resp Dis, Heerlen, Netherlands Univ Hosp Maastricht, Dept Resp Dis, Maastricht, Netherlands Univ Hosp Maastricht Maastricht Netherlands is, Maastricht, Netherlands
Titolo Testata:
RADIOTHERAPY AND ONCOLOGY
fascicolo: 2, volume: 49, anno: 1998,
pagine: 175 - 183
SICI:
0167-8140(199811)49:2<175:MHARII>2.0.ZU;2-H
Fonte:
ISI
Lingua:
ENG
Soggetto:
DOSE-RATE BRACHYTHERAPY; RATE INTRALUMINAL BRACHYTHERAPY; MALIGNANT AIRWAY-OBSTRUCTION; EXTERNAL-BEAM IRRADIATION; BRONCHOGENIC-CARCINOMA; LOCAL-CONTROL; CANCER; TUMORS; LASER;
Keywords:
non-small cell lung carcinoma; radiotherapy; brachytherapy; massive haemoptysis;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
25
Recensione:
Indirizzi per estratti:
Indirizzo: Langendijk, JA Vrije Univ Amsterdam, Acad Ziekenhuis, Dept Radiat Oncol, POB 7057, NL-1007 Vrije Univ Amsterdam POB 7057 Amsterdam Netherlands NL-1007 MB
Citazione:
J.A. Langendijk et al., "Massive haemoptysis after radiotherapy in inoperable non-small cell lung carcinoma: is endobronchial brachytherapy really a risk factor?", RADIOTH ONC, 49(2), 1998, pp. 175-183

Abstract

Background and purpose: This retrospective study was conducted to investigate whether endobronchial brachytherapy (EBB) is a risk factor for massive haemoptysis in patients primarily treated by a combination of EBB and external irradiation (XRT) for NSCLC. Materials and methods: The records of 938 patients with inoperable NSCLC who were treated with XRT and/or EBB were reviewed. The patients were divided into five groups as follows: group XRT, treated by XRT alone (n = 421); group XRTelig, treated by XRT but eligible for EBB (n = 419); group XRTEBB, primarily treated with EBB+XRT (n = 62); group EBBrec, treated by EBB for recurrence after XRT (n = 23); and group EBB, treated by EBB alone (n = 13). EBB was delivered using HDR. Patients with bronchoscopy-proven endobronchial tumour in the proximal airways, i.e. the trachea, the main bronchus or lobar bronchus were considered eligible for EBB. Results: One hundred one out of 938 patients (10.8%) died from massive haemoptysis. The incidence was 4.3% in group XRT, 13.1% in group XRTelig and 25.4% in group XRTEBB. The differences between groups XRT and XRTelig as well as between groups XRTelig and XRTEBB were statistically significant (P < 0.01). The incidence of massive haemoptysis depended significantly on the fraction size of brachytherapy. When two fractions of 7.5 Gy or a single fraction of IO Gy were used, 11.1% of the patients died from massive haemoptysis. However, when a single dose of 15 Gy was used, 47.8% died from massive haemoptysis. In the multivariate analysis, a single dose of 15 Gy EBB was the most important prognostic factor for massive haemoptysis. Conclusion: XRT+EBB as primary treatment for NSCLC does not lead to a higher risk of massive haemoptysis as compared to XRT alone when fraction sizesfor EBB of 7.5 or 10 Gy are used. However, the risk of massive haemoptysisincreases dramatically when a fraction size of 15 Gy is used. (C) 1998 Elsevier Science Ireland Ltd. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 27/10/20 alle ore 05:34:24